Prof Joerg Latus (Robert Bosch Hospital, DE) and Dr Chee Kay Cheung (University Hospitals of Leicester NHS Trust, UK) reflect on key data presented at ERA 2025 around the management of IgAN and FSGS. They highlight how real-world and clinical trial results, especially from SPARTACUS, PROTECT and DUPLEX, reinforce sparsentan’s role in reducing proteinuria and slowing kidney function decline in IgAN and FSGS.